California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a ...
Swedish neuroscience specialist BioArctic (Nasdaq Stockholm: BIOA B) said partner Eisai expects Alzheimer’s disease therapy ...
Vetter is celebrating the start of construction on its new site in Saarlouis with a traditional ground-breaking ceremony today.
Bristol Myers Squibb’s Eliquis (apixaban) is on course for one of the largest single-asset revenue collapses in ...
US biotech Inhibrx Biosciences (Nasdaq: INBX) has reported encouraging mid-stage data for its OX40 agonist INBRX-106, showing ...
US regulator the Food and Drug Administration has granted accelerated approval to Beqalzi (sonrotoclax), giving BeOne ...
Danish CNS specialist Lundbeck reported that total revenue for the first quarter of 2026 grew by +21% constant exchange rate ...
The European Commission (EC) has granted marketing authorization to expand the approved indication for Pfizer’s Hympavzi ...
US biotech MacroGenics (Nasdaq: MGNX) has agreed to sell its GMP manufacturing operations to Taiwanese contract manufacturer ...
Japan’s largest drugmaker Takeda today announced financial results for the fiscal year 2025 (period ended March 31, 2026).
Italian drugmaker Recordati reported first-quarter 2026 revenue of 713 million euros ($775 million) on Tuesday, up 5% year-on ...
The global DNA synthesis market is projected to grow from $5.7 billion in 2025 to $30.4 billion by 2035, according to a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results